Retatrutide (RETA-40) 107mg research peptide is not intended for human or animal consumption
2022 Jul 7 [cited 2025 Mar 4];185(14)
67% of individuals on the 4.8 mg dose experienced weight reduction of 15% or more (versus just 4.3% on placebo) These clinically meaningful outcomes suggest survodutide may represent an important advancement in pharmacological approaches to weight management
Expert Oversight We specialize in GLP-1 medications like semaglutide and tirzepatide for safe, proven results
State Medicaid Coverage Rules To understand why the answer to "does Medicaid cover weight loss shots" varies so widely, you need to understand how Medicaid itself works
Rights and permissions Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made